Tower Research Capital (TRC)’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.51M Sell
27,030
-18,751
-41% -$6.68M 0.25% 60
2025
Q4
$15M Buy
45,781
+27,113
+145% +$8.6M 0.36% 36
2025
Q3
$5.27M Buy
18,668
+6,957
+59% +$2.02M 0.15% 117
2025
Q2
$3.27M Sell
11,711
-8,903
-43% -$2.52M 0.09% 209
2025
Q1
$4.02M Sell
20,614
-35,192
-63% -$10.4M 0.12% 133
2024
Q4
$14.5M Buy
55,806
+21,382
+62% +$6.34M 0.29% 53
2024
Q3
$11.1M Sell
34,424
-33,292
-49% -$10.9M 0.29% 41
2024
Q2
$21.2M Buy
67,716
+11,671
+21% +$3.43M 0.36% 32
2024
Q1
$15.9M Sell
56,045
-47,522
-46% -$13.9M 0.38% 37
2023
Q4
$29.8M Buy
103,567
+78,592
+315% +$21.4M 0.37% 44
2023
Q3
$6.71M Sell
24,975
-6,282
-20% -$1.57M 0.21% 79
2023
Q2
$6.94M Buy
31,257
+7,532
+32% +$1.75M 0.23% 54
2023
Q1
$5.74M Buy
23,725
+2,912
+14% +$715K 0.18% 64
2022
Q4
$5.47M Sell
20,813
-144,545
-87% -$38.7M 0.23% 56
2022
Q3
$37.3M Buy
165,358
+54,001
+48% +$13.1M 0.61% 20
2022
Q2
$27.1M Sell
111,357
-122,473
-52% -$30M 0.61% 21
2022
Q1
$56.5M Buy
233,830
+146,736
+168% +$33.7M 0.54% 29
2021
Q4
$19.6M Buy
87,094
+13,185
+18% +$2.78M 0.34% 47
2021
Q3
$15.7M Sell
73,909
-33,458
-31% -$7.7M 0.4% 26
2021
Q2
$26.2M Sell
107,367
-19,341
-15% -$4.76M 0.68% 14
2021
Q1
$31.5M Buy
126,708
+110,857
+699% +$26.5M 0.53% 28
2020
Q4
$3.64M Sell
15,851
-19,809
-56% -$4.57M 0.11% 111
2020
Q3
$9.06M Buy
35,660
+23,739
+199% +$5.88M 0.1% 27
2020
Q2
$2.81M Buy
11,921
+10,144
+571% +$2.31M 0.12% 142
2020
Q1
$360K Buy
1,777
+954
+116% +$208K 0.02% 549
2019
Q4
$198K Sell
823
-6,956
-89% -$1.53M 0.02% 590
2019
Q3
$1.5M Sell
7,779
-11,725
-60% -$2.25M 0.1% 169
2019
Q2
$3.59M Buy
19,504
+11,381
+140% +$2.04M 0.24% 50
2019
Q1
$1.54M Sell
8,123
-8,948
-52% -$1.71M 0.09% 167
2018
Q4
$3.32M Sell
17,071
-9,273
-35% -$1.81M 0.24% 85
2018
Q3
$5.46M Sell
26,344
-8,773
-25% -$1.73M 0.4% 31
2018
Q2
$6.48M Buy
+35,117
New +$6.21M 0.36% 49
2018
Q1
Sell
-11,450
Closed -$1.99M 3209
2017
Q4
$1.99M Buy
11,450
+6,817
+147% +$1.21M 0.26% 72
2017
Q3
$864K Buy
+4,633
New +$821K 0.07% 160
2017
Q2
Sell
-1,330
Closed -$218K 2653
2017
Q1
$218K Sell
1,330
-1,923
-59% -$320K 0.02% 274
2016
Q4
$475K Buy
3,253
+2,538
+355% +$382K 0.05% 361
2016
Q3
$119K Sell
715
-963
-57% -$163K 0.01% 725
2016
Q2
$255K Sell
1,678
-1,458
-46% -$227K 0.02% 521
2016
Q1
$470K Buy
+3,136
New +$466K 0.07% 180
2015
Q4
Sell
-124
Closed -$17K 4425
2015
Q3
$17K Sell
124
-676
-85% -$107K ﹤0.01% 1862
2015
Q2
$123K Buy
800
+326
+69% +$52.2K 0.01% 648
2015
Q1
$76K Sell
474
-792
-63% -$125K 0.01% 1125
2014
Q4
$202K Sell
1,266
-20,148
-94% -$3.14M 0.02% 305
2014
Q3
$3.01M Buy
21,414
+20,729
+3,026% +$2.71M 0.34% 55
2014
Q2
$81K Buy
685
+133
+24% +$15.4K 0.01% 1012
2014
Q1
$68K Sell
552
-3,660
-87% -$444K 0.01% 893
2013
Q4
$480K Sell
4,212
-17,911
-81% -$2.04M 0.08% 192
2013
Q3
$2.48M Buy
22,123
+21,649
+4,567% +$2.35M 0.27% 78
2013
Q2
$47K Buy
+474
New +$49.2K ﹤0.01% 985

Other funds holding AMGN

Tower Research Capital (TRC)'s AMGN Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Amgen (AMGN) stake by 41% in Q1 2026, selling an estimated $6.68M and leaving 27,030 shares worth $9.51M. The position accounts for 0.25% of the portfolio, ranked #60.

Tower Research Capital (TRC) first reported a position in AMGN in Q2 2013 and has held it in 49 quarters since. The position peaked at $56.5M in Q1 2022. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Tower Research Capital (TRC) held 27,030 shares of Amgen worth $9.51M as of Q1 2026.
  • Tower Research Capital (TRC) sold 18,751 Amgen shares in Q1 2026, an estimated $6.68M.
  • Amgen made up 0.25% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #60 holding.
  • Tower Research Capital (TRC) first reported a position in Amgen in Q2 2013 and has held it in 49 quarters since.
  • Tower Research Capital (TRC)'s Amgen position peaked at $56.5M in Q1 2022.
  • 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.